Company research
KYNTRA BIO, INC.
CIK 921299Updated Sep 25, 2026
SecurityKYNB · NASDAQ · equity
Name history
FIBROGEN INC · through Jan 7, 2026
KYNB price & chart
Loading TradingView…
NASDAQ:KYNB on TradingView ↗About the company
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.
In the news
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation ↗
Recent filings
8-K filing
SCHEDULE 13G/A filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 119,594,000Source | 214,525,000Source | 423,529,000Source | 610,087,000Source |
| Property, Plant and Equipment, NetUSD | — | 0Source | 13,126,000Source | 20,605,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 47,872,000Source | 50,482,000Source | 113,688,000Source | 155,700,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 216,000Source | 481,000Source | 12,553,000Source | 16,299,000Source |
| Inventory, NetUSD | 3,743,000Source | 3,155,000Source | 41,565,000Source | 40,436,000Source |
| Assets, CurrentUSD | 99,073,000Source | 196,509,000Source | 331,559,000Source | 492,826,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,136,000Source | 31,542,000Source | 41,855,000Source | 14,083,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 0Source | 68,093,000Source | 79,893,000Source |
| Other Assets, NoncurrentUSD | 361,000Source | 1,405,000Source | 3,803,000Source | 5,282,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 115,119,000Source | 398,160,000Source | 585,728,000Source | 611,567,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,012,000Source | 1,009,000Source | 988,000Source | 942,000Source |
| Additional Paid in CapitalUSD | 1,677,179,000Source | 1,668,620,000Source | 1,643,641,000Source | 1,541,019,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,706,047,000Source | -1,889,499,000Source | -1,841,920,000Source | -1,557,688,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,182,000Source | -5,732,000Source | -6,875,000Source | -5,720,000Source |
| Stockholders' Equity Attributable to ParentUSD | -30,038,000Source | -225,602,000Source | -204,166,000Source | -21,447,000Source |
| Liabilities and EquityUSD | 119,594,000Source | 214,525,000Source | 423,529,000Source | 610,087,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 29,242,000Source | 133,306,000Source | 217,668,000Source | 273,562,000Source |
| Operating Lease, Liability, CurrentUSD | — | 0Source | 14,077,000Source | 10,292,000Source |
| Accounts Payable, CurrentUSD | 3,745,000Source | 5,064,000Source | 17,960,000Source | 30,758,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 0Source | 66,537,000Source | 79,593,000Source |
| Other Liabilities, NoncurrentUSD | 82,000Source | 822,000Source | 2,858,000Source | 6,440,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | — | 19,967,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 20,183,000Source | 62,035,000Source | 172,891,000Source | 219,773,000Source |
| Deferred Tax Liabilities, NetUSD | 10,000Source | 20,000Source | 13,994,000Source | 14,032,000Source |
| Redeemable Noncontrolling Interest, Equity, Carrying AmountUSD | 21,480,000Source | 21,480,000Source | 21,480,000Source | — |
| Short-term InvestmentsUSD | 41,106,000Source | 0Source | 121,898,000Source | 266,308,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 183,452,000Source | -47,579,000Source | -284,232,000Source | -293,654,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,576,000Source | 25,215,000Source | 50,767,000Source | 65,601,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 2,543,000Source | 6,737,000Source | -3,433,000Source | -765,000Source |
| Increase (Decrease) in InventoriesUSD | -5,362,000Source | -22,284,000Source | 1,695,000Source | 10,999,000Source |
| Increase (Decrease) in Accounts PayableUSD | -27,654,000Source | 14,512,000Source | -15,514,000Source | 5,909,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -4,774,000Source | -137,999,000Source | -315,021,000Source | -145,933,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 35,419,000Source | 125,993,000Source | 153,657,000Source | 89,116,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 38,000Source | 266,000Source | 2,519,000Source | 3,741,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 69,000Source | 354,000Source | 237,000Source | 5,167,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -86,028,000Source | -255,000Source | 122,749,000Source | 46,776,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -54,306,000Source | -11,510,000Source | -42,012,000Source | -15,523,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 7,830,000Source | 16,207,000Source | 54,000Source | 104,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,345,000Source | 23,445,000Source | 50,767,000Source | 65,601,000Source |
| Amortization of Debt Issuance CostsUSD | 1,100,000Source | — | — | — |
| DepreciationUSD | 713,000Source | 2,654,000Source | 9,518,000Source | 10,017,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | 0Source | -2,551,000Source | -4,000Source | 1,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | -2,500,000Source | — | — |
| Gain (Loss) on Disposition of BusinessUSD | 52,553,000Source | — | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | 1,700,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | -6,583,000Source | — | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -58,204,000Source | -153,098,000Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 241,656,000Source | 105,519,000Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 2,638,000Source | 1,573,000Source |
| Income Tax Expense (Benefit)USD | -90,000Source | -269,000Source | 3,000Source | 358,000Source |
| Net Income (Loss) Attributable to ParentUSD | 183,452,000Source | -47,579,000Source | -284,232,000Source | -293,654,000Source |
| Nonoperating Income (Expense)USD | 2,943,000Source | 5,296,000Source | 10,480,000Source | 7,596,000Source |
| Operating Lease, ExpenseUSD | — | 0Source | — | — |
| Payments of Financing CostsUSD | 46,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | 0Source | 139,000Source | 3,731,000Source | 4,184,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 6,440,000Source | 29,621,000Source | 147,752,000Source | 140,734,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 27,709,000Source | 49,330,000Source | 115,252,000Source | 124,688,000Source |
| Operating Income (Loss)USD | -45,895,000Source | -150,416,000Source | -281,815,000Source | -301,025,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -58,294,000Source | -153,367,000Source | -286,867,000Source | -294,869,000Source |
| Income Tax Expense (Benefit)USD | -90,000Source | -269,000Source | 3,000Source | 358,000Source |
| Net Income (Loss) Attributable to ParentUSD | 183,452,000Source | -47,579,000Source | -284,232,000Source | -293,654,000Source |
| Earnings Per Share, BasicUSD per share | 45.37Source | -0.48Source | -2.92Source | -3.14Source |
| Earnings Per Share, DilutedUSD per share | 45.37Source | -0.48Source | -2.92Source | -3.14Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,043,000Source | 100,044,000Source | 97,303,000Source | 93,582,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 4,043,000Source | 100,044,000Source | 97,303,000Source | 93,582,000Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 52,335,000Source | 180,037,000Source | 429,567,000Source | 441,759,000Source |
| Current Income Tax Expense (Benefit)USD | -90,000Source | -269,000Source | 3,000Source | 358,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -47,917,000Source | -142,819,000Source | -328,475,000Source | -307,056,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -58,204,000Source | -153,098,000Source | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -14.4Source | -1.53Source | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -14.4Source | -1.53Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 241,656,000Source | 105,519,000Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | 2,638,000Source | 1,573,000Source |
| Interest ExpenseUSD | 8,759,000Source | 8,247,000Source | 15,532,000Source | 1,440,000Source |
| Interest Expense, DebtUSD | — | — | 7,400,000Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | -12,399,000Source | -2,951,000Source | -5,052,000Source | 6,156,000Source |
| Nonoperating Income (Expense)USD | 2,943,000Source | 5,296,000Source | 10,480,000Source | 7,596,000Source |
| Operating Lease, ExpenseUSD | — | 0Source | — | — |
| Research and Development ExpenseUSD | 23,517,000Source | 95,692,000Source | 282,861,000Source | 296,791,000Source |
Filing attachments
kynb-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 kynb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update • Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026 • Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (…
Read attachment ↗kynb-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 kynb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update • Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026 • Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patient…
Read attachment ↗kynb-ex99_1.htm · 8-K · 2026-03-16
EX-99.1 2 kynb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026 • Positive results from the investigator-sponsored study of FG-3246 in combination with en…
Read attachment ↗fgen-ex99_1.htm · 8-K · 2026-01-07
EX-99.1 4 fgen-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum • Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare disease • Kyntra Bio will begin trading on Nasdaq under the trading symbol “KYNB” effective January 8th SAN FRANCISCO, January 7, 2026 (GLOBE NEWSWIRE) - FibroGen, Inc. (Nasdaq: FGEN), today announced it is r…
Read attachment ↗fgen-ex99_1.htm · 8-K · 2025-11-10
EX-99.1 2 fgen-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update • Completed the sale of FibroGen China to AstraZeneca for approximately $220 million • Initiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC) • Reached agreement with the U.S. Food and Drug Administration (FDA) on important d…
Read attachment ↗fgen-ex99_1.htm · 8-K · 2025-09-05
EX-99.1 2 fgen-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On September 2, 2025, the Company announced that it completed the sale of FibroGen International (Hong Kong) Ltd., (including its subsidiaries, “FibroGen China”) to AstraZeneca Treasury Limited (“AstraZeneca”), for a total consideration of approximately $220 million, subject to certain customary adjustments as set forth in the purchase agreement, comprised of $85 million…
Read attachment ↗